10 Teva Pharmaceutical Industries Ltd Analyst Ratings, Earnings, Dividends and Insider Trades | $TEVA | NASDAQ:TEVA | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Teva Pharmaceutical Industries Ltd Company Profile (NASDAQ:TEVA) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 3 Sell Rating(s), 8 Hold Rating(s), 8 Buy Rating(s)Consensus Rating:Hold (Score: 2.26)Consensus Price Target: $48.71 0.09% downside) Analysts' Ratings History for Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare3/7/2014BarclaysUpgradeEqual Weight -> Overweight$42.00 -> $65.00View 3/6/2014Leerink SwannUpgradeMarket Perform -> Outperform$65.00View 3/3/2014Citigroup Inc.Boost Price TargetBuy$50.00 -> $56.00View 2/25/2014BMO Capital MarketsBoost Price Target$46.00View 2/10/2014Leerink SwannBoost Price Target$42.00 -> $48.00View 2/7/2014ZacksReiterated RatingNeutral -> Neutral$47.00View 1/29/2014TheStreetUpgradeHold -> BuyView 1/29/2014CRT CapitalBoost Price TargetBuy$50.00 -> $55.00View 1/28/2014Citigroup Inc.Boost Price Target$47.00 -> $50.00View 1/6/2014RBC CapitalInitiated CoverageSector Perform$39.00View 12/16/2013ZacksReiterated RatingNeutral -> Neutral$42.00View 11/20/2013SusquehannaUpgradeNeutral -> Positive$43.00 -> $50.00View 11/4/2013Jefferies GroupLower Price TargetHold$42.00 -> $39.00View 11/4/2013JPMorgan Chase & Co.DowngradeNeutral -> Underweight$43.00 -> $38.00View 10/31/2013BMO Capital MarketsReiterated RatingOutperform$49.00 -> $44.00View 10/30/2013Sanford C. BernsteinLower Price TargetOutperform$47.00 -> $43.00View 10/30/2013Goldman SachsReiterated RatingSellView 10/25/2013Citigroup Inc.Initiated CoverageBuy$47.00View 10/14/2013OppenheimerInitiated CoverageMarket PerformView 9/26/2013ZacksReiterated RatingNeutral -> Neutral$40.00View 9/13/2013Morgan JosephLower Price TargetOverweight -> Neutral$45.00 -> $43.00View 9/13/2013JPMorgan Chase & Co.DowngradeOverweight -> Neutral$45.00 -> $43.00View 8/5/2013Morgan StanleyDowngradeEqual Weight -> UnderweightView 8/2/2013Canaccord GenuityReiterated RatingHoldView 7/31/2013Morgan StanleyReiterated RatingEqual Weight -> Equal Weight$42.00 -> $40.00View 7/30/2013Goldman SachsDowngradeNeutral -> Sell$41.00 -> $40.00View 7/29/2013UBS AGLower Price TargetNeutral$41.00 -> $40.00View 7/23/2013ZacksReiterated RatingNeutral -> Neutral$43.00View 7/15/2013TheStreetReiterated RatingBuyView 7/3/2013TheStreetReiterated RatingBuyView 6/19/2013Maxim GroupReiterated RatingBuy$56.00View 6/11/2013TheStreetUpgradeHold -> BuyView 6/3/2013TheStreetReiterated RatingHoldView 5/21/2013TheStreetReiterated RatingHoldView 5/10/2013TheStreetReiterated RatingHoldView 5/9/2013BMO Capital MarketsInitiated CoverageOutperformView 5/7/2013ZacksReiterated RatingNeutral -> Neutral$40.00View 4/29/2013TheStreetReiterated RatingHoldView 4/18/2013TheStreetReiterated RatingHoldView 4/9/2013ZacksReiterated RatingNeutral -> Neutral$41.00View 4/8/2013TheStreetReiterated RatingHoldView 3/28/2013TheStreetReiterated RatingHoldView 3/18/2013TheStreetReiterated RatingHoldView 3/18/2013Wells Fargo & Co.DowngradeOutperform -> Market PerformView 3/7/2013TheStreetReiterated RatingHoldView 2/25/2013ArgusDowngradeBuy -> Hold$48.00View 2/14/2013TheStreetReiterated RatingHoldView 2/11/2013ZacksReiterated RatingNeutral -> Neutral$41.00View 2/8/2013Canaccord GenuityDowngradeBuy -> Hold$50.00 -> $45.00View 1/21/2013ZacksReiterated RatingNeutral -> Neutral$40.00View 1/11/2013TheStreetReiterated RatingHoldView 12/12/2012SusquehannaReiterated RatingNeutral$43.00View 12/12/2012Leerink SwannDowngradeOutperform -> Market PerformView 12/12/2012Wells Fargo & Co.Reiterated RatingOutperformView 12/6/2012ArgusReiterated RatingBuy$48.00View 12/3/2012Canaccord GenuityReiterated RatingBuy -> Buy$50.00View 12/3/2012Credit SuisseLower Price TargetOutperform$51.00 -> $50.00View 12/3/2012Cowen and CompanyReiterated RatingOutperformView 12/3/2012Wells Fargo & Co.Reiterated RatingOutperformView 12/3/2012UBS AGDowngradeBuy -> Neutral$52.00 -> $41.00View 11/30/2012Buckingham ResearchDowngradeBuy -> NeutralView 11/5/2012ZacksReiterated RatingNeutral -> Neutral$44.00View 10/16/2012Canaccord GenuityReiterated RatingBuy$50.00View 9/27/2012ZacksReiterated RatingNeutral -> Neutral$43.00View 9/18/2012GuggenheimInitiated CoverageNeutral$45.00View 9/12/2012Leerink SwannReiterated RatingOutperformView 8/23/2012Canaccord GenuityReiterated RatingBuy$52.00View 8/6/2012ZacksReiterated RatingNeutral -> Neutral$41.00View 8/3/2012OppenheimerReiterated RatingMarket PerformView 8/3/2012Needham & CompanyReiterated RatingHoldView 8/3/2012RBC CapitalReiterated RatingView 8/3/2012Canaccord GenuityReiterated RatingBuyView 7/18/2012ZacksReiterated RatingNeutral -> Neutral$44.00View 6/25/2012Goldman SachsBoost Price Target$46.00View 6/25/2012UBS AGReiterated RatingBuyView 6/25/2012Canaccord GenuityReiterated RatingBuyView 6/18/2012Deutsche BankReiterated RatingBuyView 6/12/2012Canaccord GenuityReiterated RatingBuyView 5/29/2012Morgan StanleyLower Price TargetEqual Weight$47.00 -> $44.00View 5/25/2012BarclaysReiterated RatingEqual WeightView 5/25/2012Canaccord GenuityReiterated RatingBuyView 5/25/2012UBS AGLower Price TargetBuy$60.00 -> $52.00View 5/25/2012Citigroup Inc.Lower Price Target$49.00View 5/25/2012Needham & CompanyReiterated RatingHoldView 5/23/2012AurigaInitiated CoverageHold$45.00View 5/11/2012ZacksReiterated RatingNeutral -> Neutral$44.00View 5/10/2012Needham & CompanyDowngradeStrong-Buy -> HoldView 5/1/2012ZacksReiterated RatingNeutral -> Neutral$48.00View 3/20/2012Standpoint ResearchReiterated RatingBuyView (Data available from 3/12/2012 forward) Earnings History for Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare2/6/2014Q413$1.26$1.42$5.19 billion$5.40 billionViewN/AView 10/31/2013Q313$1.26$1.27$5.00 billion$5.06 billionViewN/AView 8/1/2013Q213$1.20$1.20$4.94 billion$4.90 billionViewN/AView 5/2/2013Q113$1.10$1.12$4.85 billion$4.90 billionViewN/AView 2/7/2013Q412$1.33$1.32$5.26 billion$5.20 billionViewN/AView 11/1/2012Q312$1.25$1.28$5.08 billion$5.00 billionViewN/AView 8/2/2012$1.28$1.28ViewN/AView 5/9/2012$1.44$1.47ViewN/AView 2/15/2012$1.58$1.59ViewN/AView 11/2/2011$1.22$1.25ViewN/AView 7/27/2011$1.08$1.10ViewN/AView 5/11/2011$1.03$1.04ViewN/AView 2/8/2011$1.28$1.25ViewN/AView (Data available from 1/1/2011 forward) Dividend History for Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA)AnnouncedPeriodAmountEx-Dividend DateRecord DatePayable DateShare2/4/2014$0.342/20/20142/24/20143/10/2014 11/1/2013quarterly$0.3311/18/201311/20/201312/2/2013 8/5/2013quarterly$0.328/16/20138/20/20139/3/2013 8/1/2013quarterly$0.328/20/20139/2/2013 5/6/2013special$0.325/16/20135/20/20136/3/2013 2/8/2013quarterly$0.312/19/20132/21/20133/7/2013 (Data available from 1/1/2013 forward) Insider Trading History for Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA)No insider trades for this company have been tracked by Analyst Ratings Network About Teva Pharmaceutical Industries Ltd Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva's active pharmaceutical ingredient (API) business provides vertical integration to Teva's own pharmaceutical production. The Company's global operations are conducted from North and Latin America to Europe and Asia. Teva operates a number of subsidiaries in such countries as Canada, Croatia, the Czech Republic, France, Germany, Hungary, Ireland, Israel, Japan, Poland, the Russian Federation, Spain, the Netherlands, the United Kingdom and the United States. In February 2014, the Company's subsidiary, Train Merger Sub, Inc, fully acquired NuPathe Inc. Headlines: (3/11) Teva to Pay $27.6 Million to Settle Clozapine Payoff Case (3/11) Teva settles Medicaid false billing case tied to Chicago doctor (3/10) Teva Pharmaceuticals and Volunteers in Medicine Partner to Expand Access to Healthcare in the U.S. (3/12) Teva settles Medicaid false billing case (3/7) Teva Announces Launch of Generic Xeloda® Tablets 150 MG and 500 MG in the United States (3/10) Teva, Lafarge, Hyundai, Australia: Intellectual Property (3/10) Teva Copaxone Appeal Action Delayed by U.S. Supreme Court (2/28) Teva to Present at the Cowen & Company 34th Annual Healthcare Conference Industry, Sector and Symbol: Sector: Healthcare Industry: N/A Sub-Industry: N/A Exchange: NASDAQ Symbol: TEVA CUSIP: Key Metrics: Previous Close: $49.2650 Day Moving Average: $46.346200 Day Moving Average: $41.1599 P/E Ratio: 33.06P/E Growth: N/AMarket Cap: $41.348BCurrent Quarter EPS Consensus Estimate: $4.53 EPS Additional Links: View TEVA on Google FinanceView TEVA on Yahoo FinanceView TEVA's Company Profile on ReutersSearch for Teva Pharmaceutical Industries Ltd on Google Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) Chart for Wednesday, March, 12, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.